Your browser doesn't support javascript.
loading
UK Prescribing Safety Assessment (PSA): The development, implementation and outcomes of a national online prescribing assessment.
Magavern, Emma F; Hitchings, Andrew; Bollington, Lynne; Wilson, Kurt; Hepburn, David; Westacott, Rachel J; Sam, Amir H; Caulfield, Mark J; Maxwell, Simon.
Afiliación
  • Magavern EF; William Harvey Research Institute, Queen Mary University of London, London, UK.
  • Hitchings A; St George's, University of London, London, UK.
  • Bollington L; UK Prescribing Safety Assessment Partnership, c/o British Pharmacological Society, Medical Schools Council-British Pharmacological Society, London, UK.
  • Wilson K; The University of Manchester, Manchester, UK.
  • Hepburn D; Hull York Medical School, Allam Medical Building, University of Hull, Hull, UK.
  • Westacott RJ; Birmingham Medical School, Institute of Clinical Sciences, College of Medical & Dental Sciences, University of Birmingham, Birmingham, UK.
  • Sam AH; Imperial College School of Medicine, Imperial College London, London, UK.
  • Caulfield MJ; William Harvey Research Institute, Queen Mary University of London, London, UK.
  • Maxwell S; Clinical Pharmacology Unit, Medical Education Centre, Western General Hospital, University of Edinburgh, Edinburgh, UK.
Br J Clin Pharmacol ; 90(2): 493-503, 2024 02.
Article en En | MEDLINE | ID: mdl-37793701
ABSTRACT

AIMS:

The United Kingdom (UK) Prescribing Safety Assessment (PSA) is a 2-h online assessment of basic competence to prescribe and supervise the use of medicines. It has been undertaken by students and doctors in UK medical and foundation schools for the past decade. This study describes the academic characteristics and performance of the assessment; longitudinal performance of candidates and schools; stakeholder feedback; and surrogate markers of prescribing safety in UK healthcare practice.

METHODS:

We reviewed the performance data generated by over 70 000 medical students and 3700 foundation doctors who have participated in the PSA since its inception in 2013. These data were supplemented by Likert scale and free text feedback from candidates and a variety of stakeholder groups. Further data on medication incidents, collected by national reporting systems and the regulatory body, are reported, with permission.

RESULTS:

We demonstrate the feasibility, high quality and reliability of an online prescribing assessment, uniquely providing a measure of prescribing competence against a national standard. Over 90% of candidates pass the PSA on their first attempt, while a minority are identified for further training and assessment. The pass rate shows some variation between different institutions and between undergraduate and foundation cohorts. Most responders to a national survey agreed that the PSA is a useful instrument for assessing prescribing competence, and an independent review has recommended adding the PSA to the Medical Licensing Assessment. Surrogate markers suggest there has been improvement in prescribing safety in practice, temporally associated with the introduction of the PSA but other factors could be influential too.

CONCLUSIONS:

The PSA is a practical and cost-effective way of delivering a reliable national assessment of prescribing competence that has educational impact and is supported by the majority of stakeholders. There is a need to develop national systems to identify and report prescribing errors and the harm they cause, enabling the impact of educational interventions to be measured.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Competencia Clínica / Evaluación Educacional Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Br J Clin Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Competencia Clínica / Evaluación Educacional Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Br J Clin Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Reino Unido